ArticleInfection and drug resistance2023
Within-Host Resistance and Virulence Evolution of a Hypervirulent Carbapenem-Resistant
Article in Infection and drug resistance, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 17 citations in OpenAlex.
- Short-Term Within-Host Genomic Diversity and Clone Turnover of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Prevalence and Multidrug Resistance of WHO-Priority Bacterial Pathogens in a Romanian Intensive Care Unit.Journal of clinical medicine · 2026Article
- Comparative Proteomic Profiling of ClinicalJournal of extracellular biology · 2026Article
- Characterization of a Phage vB_LZ 2044 Deriving from K1-Type Hypervirulent Klebsiella pneumoniae Efficient Against Liver Infection Mice Model.Probiotics and antimicrobial proteins · 2026Article
- Parallel microevolution of multidrug resistance and hypermucoviscosity in two carbapenem-resistant Pseudomonas aeruginosa clinical isolates with strikingly divergent virulence outcomes.BMC microbiology · 2026Article
- Genomic Characterization of Antimicrobial Resistance and Virulence in ST11 Carbapenem-ResistantInfection and drug resistance · 2026Article
- Hypervirulent Klebsiella pneumoniae have better clinical outcomes than classical Klebsiella pneumoniae for lower respiratory tract infection patients.BMC microbiology · 2025Article
- Active screening and molecular epidemiological characteristics of fecal colonization by carbapenem-resistantFrontiers in public health · 2025Article
- Concurrent classical and hypervirulentFrontiers in cellular and infection microbiology · 2025Article
- ESKAPE in China: epidemiology and characteristics of antibiotic resistance.Emerging microbes & infections · 2024Review
- Epidemiology, antimicrobial resistance profile and management of carbapenem-resistant Klebsiella pneumoniae among mothers with suspected sepsis in Ethiopia.Annals of clinical microbiology and antimicrobials · 2024Article
- Prevalence of Infections and Antimicrobial Resistance of ESKAPE Group Bacteria Isolated from Patients Admitted to the Intensive Care Unit of a County Emergency Hospital in Romania.Antibiotics (Basel, Switzerland) · 2024Article
- TiOMicroorganisms · 2024Review
- Multidrug-resistant ST11-KL64 hypervirulentFrontiers in pediatrics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hypervirulent carbapenem-resistant Methods: The bacterial identification, antimicrobial susceptibility, hypermucoviscosity, virulence factors, MLST and serotypes were profiled.The clonal homology and plasmid acquisition among hv-CRKP strains were detected by XbaI and S1-PFGE. The virulence potential of the strains was evaluated using Results: Four Conclusion: This study shows that ST11-KL64 hv-CRKP can further evolve to acquire aminoglycoside resistance accompanied by decreased virulence to adapt to antibiotic pressure in the host.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.